These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. [Current aspects of diagnosis and treatment of atopic diseases complicated by secondary immunodeficiency]. Mikheeva GN; Khaitov RM Ter Arkh; 1998; 70(4):54-60. PubMed ID: 9612905 [TBL] [Abstract][Full Text] [Related]
30. [Comparative characteristic of the treatment efficacy in patients with often recurrent acute respiratory infections complicated with immunodeficiency treated with likopid]. Chop'iak VV; Pot'omkina HO Lik Sprava; 2013 Mar; (2):106-17. PubMed ID: 24605620 [TBL] [Abstract][Full Text] [Related]
31. [Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide]. Ushkalova EA; Zyryanov SK; Zatolochina KE Ter Arkh; 2019 Dec; 91(12):122-127. PubMed ID: 32598599 [TBL] [Abstract][Full Text] [Related]
32. [Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine]. Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV Bioorg Khim; 2006; 32(4):424-31. PubMed ID: 16909867 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic and prophylactic effects of romurtide against experimental animal infections. Niki Y; Tatara O Adv Exp Med Biol; 1992; 319():185-91. PubMed ID: 1414593 [No Abstract] [Full Text] [Related]
34. [Characteristics and clinical use of immunostimulants]. Shirinskiĭ VS; Zhuk EA Ter Arkh; 1990; 62(12):125-32. PubMed ID: 1707558 [No Abstract] [Full Text] [Related]
35. A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers. Higgins PG; Barrow GI; Galbraith AW; Frost H; Tyrrell DA Antiviral Res; 1989 Aug; 12(1):49-52. PubMed ID: 2596839 [TBL] [Abstract][Full Text] [Related]
37. New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP. Chedid L; Audibert F Springer Semin Immunopathol; 1985; 8(4):401-12. PubMed ID: 4089758 [No Abstract] [Full Text] [Related]
38. Approaches to cancer therapy using biological response modifiers. MacEwen EG Vet Clin North Am Small Anim Pract; 1985 May; 15(3):667-88. PubMed ID: 2409659 [No Abstract] [Full Text] [Related]
39. [The influence of type MDP immunomodulators on secretion and activity of cytokines]. Dzierzbicka K; Gozdowska M; Kołodziejczyk AM Postepy Biochem; 1998; 44(3):216-9. PubMed ID: 10022040 [No Abstract] [Full Text] [Related]
40. Restorative effect of MDP-Lys (L18) on leukopenia of cancer patient treated with radiotherapy. Okawa T; Kikuchi Y; Watarai J; Dokiya T; Tanaka T; Saito Y; Hirokawa Y; Takegawa Y; Hata K Nihon Igaku Hoshasen Gakkai Zasshi; 1988 Apr; 48(4):514-22. PubMed ID: 3231516 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]